Royalty Pharma plc (RPRX) concluded trading on Wednesday at a closing price of $32.75, with 6.09 million shares of worth about $199.31 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 20.85% during that period and on May 07, 2025 the price saw a gain of about 1.99%. Currently the company’s common shares owned by public are about 445.99M shares, out of which, 342.82M shares are available for trading.
Stock saw a price change of -0.21% in past 5 days and over the past one month there was a price change of 5.54%. Year-to-date (YTD), RPRX shares are showing a performance of 28.38% which increased to 15.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.05 but also hit the highest price of $34.20 during that period. The average intraday trading volume for Royalty Pharma plc shares is 4.53 million. The stock is currently trading 1.31% above its 20-day simple moving average (SMA20), while that difference is up 0.76% for SMA50 and it goes to 12.31% higher than SMA200.
Royalty Pharma plc (NASDAQ: RPRX) currently have 445.99M outstanding shares and institutions hold larger chunk of about 75.53% of that.
The stock has a current market capitalization of $18.81B and its 3Y-monthly beta is at 0.48. PE ratio of stock for trailing 12 months is 17.08, while it has posted earnings per share of $1.92 in the same period. Its PEG reads 1.49 and has Quick Ratio of 1.44 while making debt-to-equity ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 2.06% while standing at 2.49% over the month.
Stock’s fiscal year EPS is expected to rise by 8.71% while it is estimated to increase by 14.64% in next year. EPS is likely to grow at an annualized rate of 11.50% for next 5-years, compared to annual growth of -21.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on June 03, 2024 offering a Neutral rating for the stock and assigned a target price of $28 to it. Coverage by UBS stated Royalty Pharma plc (RPRX) stock as a Buy in their note to investors on June 14, 2022, suggesting a price target of $47 for the stock. On May 13, 2022, Scotiabank Initiated their recommendations, while on April 27, 2022, Goldman Initiated their ratings for the stock with a price target of $56. Stock get an Overweight rating from JP Morgan on April 14, 2022.
